Please login to the form below
hematology
This page shows the latest hematology news and features for those working in and with pharma, biotech and healthcare.
bluebird bio submits US application for sickle cell gene therapy
cel. Results from a detailed investigation of the case were presented at the American Society of Hematology Annual Meeting and Exposition, alongside details from another case of persistent anaemia in an
Latest news
-
Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab
Updated results from the phase 2 NP30179 study in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), presented by Genentech at the American Society of Hematology Annual
-
FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies
Results from a detailed investigation of the case were presented at the American Society of Hematology Annual Meeting and Exposition earlier this month, alongside details from another case of persistent anaemia
-
Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study
Results from the study, which the company presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana, showed an estimated 82.3% of iptacopan-treated
-
Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study
The data was shared during the 2022 American Society of Hematology Annual Meeting. ... The study findings were presented during the 2022 American Society of Hematology (ASH) Annual Meeting.
-
Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma
with previously untreated DLBCL and were presented at the 64th American Society of Hematology (ASH) Annual Meeting &Exposition.
More from news
Approximately 7 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
ASH 2022: bad blood but big advances
That was certainly the case at the American Society of Hematology’s 64th annual meeting in New Orleans in December 2022, where even the surprise appearance of the modern-day Queen ... Notably, the Joint Symposium between ASH and the European Hematology
-
Attracting doctors to low-demand specialties
A brief glance at the programme for the major US haematology congress, held by the American Society of Hematology, tells its own story, with most sessions being dedicated to haematological malignancies
-
Deal Watch November 2016
This does not typically include royalty payments. 2. Ataga et al, Abstract, American Society of Hematology (ASH), December 2016.
-
Deal Watch July 2016
Portfolio of early-stage hematology candidates &option for recombinant pegasparaginase. Licence, option.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Nanobiotix strengthens US leadership team
Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.
-
TxCell appoints global scientific advisory board
Prof Chiara Bonini (pictured left) is currently head of the experimental hematology unit at the San Raffaele Scientific Institute, a position she has held since 2008.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
5 ways we’re enhancing our services to support our clients in 2023
Jon Koch:We’re continuing to expand partnerships with leading networks of global clinicians in dermatology, hepatology, oncology, and hematology to deliver actionable insights that meet the needs of our clients
-
Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
FIDE joins other Expert Partnerships at FH including IHEP, which specializes in diseases of the liver and i-ONE, which specializes in oncology and hematology.
-
Medscape Education Global
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide.
-
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians. In this customer story, we summarize the outcomes from an ongoing project where our client is leveraging a variety of Impetus
-
Highlights in haematologic malignancy from ASH 2018
Earlier this month, Porterhouse Medical attended the 60. th. American Society of Hematology (ASH) Annual Meeting (). The ASH congress is the most comprehensive haematology event of the year, attracting 25, 000
More from PMHub
Approximately 3 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
- Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
